[Evaluation on the efficacy of recombinant hepatitis B vaccine booster immunization in 2789 children aged over 10 years].

OBJECTIVE: To study the efficiency of booster immunization with different recombinant hepatitis B vaccines. METHODS: 2789 children aged over 10 years who had completed the basic immunization of hepatitis B vaccine under 1 year old were selected. All the sampled children were classified into four groups (A, B, C and D) and immunized with different hepatitis B vaccines produced by different companies respectively. Before booster immunization, their blood plasma specimens were detected for hepatitis B virus (HBV) surface antigen (HBsAg), antibodies to HBV surface antigen (anti-HBs) and antibodies to HBV core antigen (anti-HBc) by chemiluminescence. In each group, the anti-HBs positive children were immunized with one dosage and anti-HBs negative children were immunized three dosages of the same vaccine. Their blood specimens were collected again after 1 month, and detected for anti-HBs. RESULTS: The anti-HBs positive rates of A, B, C and D group were 36.43%, 37.59%, 42.91% and 46.46% respectively before immunization while 89.20%, 91.52%, 90.96% and 85.45% respectively after immunization with one dosage, 99.12%, 99.47%, 98.87% and 98.85% respectively after immunization with three dosages. The differences of anti-HBs positive rates in the four respective groups showed statistical significances between any two rates of pre-immunization, post-immunization with one dosage and post-immunization with three dosages (all P < 0.05). The anti-HBs positive conversion rates of four groups were 83.01%, 86.41%, 84.16% and 72.82% respectively after immunization with one dosage. The anti-HBs positive conversion rate of four groups were 98.62%, 99.16%, 98.03% and 97.84% respectively after immunization with three dosages and the difference of positive conversion rates in each group showed statistical significances between booster immunization with one dosage and booster immunization with three dosages. The average GMTs in anti-HBs positive children in the four groups were 2853.21, 6254.23, 3581.40 and 3021.32 mIU/ml respectively after immunization with one dosage. The average GMTs of anti-HBs negative children in the four groups were 273.08, 648.52, 387.87 and 245.36 mIU/ml respectively after immunization with one dosage, and were 632.30, 2341.14, 563.97 and 394.08 mIU/ml respectively after immunization with three dosages. CONCLUSION: Our data showed that it would be suitable to anyone to use the four vaccines for anti-HBs positive children aged over 10 years with one dosage and for anti-HBs negative children aged over 10 years with three dosage booster immunization.

[Expression and clinical significance of IL-17 and IL-21 in patients with acute leukemia].

This study was aimed to investigate the effects of peripheral blood Th17 cells, IL-17 and IL-21 in the occurrence and development of acute leukemia. 60 patients with acute leukemia (19 patients with ALL, 41 patients with AML) were divided into non-remission group (group A, n=24), remission group (group B, n=36); 25 healthy volunteers were used as control group (group C). In addition to this, these 60 patients were divided into infection group (n=32) and non-infection group (n=28) on the basis of infection status. The concentration of IL-17 and IL-21 in the peripheral blood mononuclear cell culture supernatant after stimulation with anti-CD3 and anti-CD28 mAb were determined with ELISA. The expression of CD4+ IL-17+ cells was determined by flow cytometry. The results showed that (1) the concentrations of IL-17 and IL-21, and proportion of Th17 cells in group A and group B were much lower than those in group C (p<0.05); (2) the expression levels of IL-17 and IL-21, and the proportion of Th17 cells in group A were lower than those in group B (p<0.05); (3) the expression levels of Th17 and IL-17 in infection group were lower than those in non-infection group (p<0.05). It is concluded that Th17 cells may play important roles in the occurrence and development of acute leukemia through secreting IL-17 and IL-21, and their functional level can partially reflect the status of leukemia and can be used to evaluate the risks of infection in patients with leukemia.

In vitro observations on the influence of copper peptide aids for the LED photoirradiation of fibroblast collagen synthesis.

OBJECTIVE: The purpose of this study was to evaluate the influence of Cu-GHK aids for the LED-PI on fibroblast proliferation and collagen production in vitro. BACKGROUND DATA: Light-emitting diode photoirradiation (LED-PI) and copper-glycyl-L-histidyl-L-lysine complex (Cu-GHK) treatment may be useful in accelerating the rate of wound healing. Red LED (625-635 nm) was used as a light source for LED-PI. In the process of wound healing, Cu-GHK was shown to be an activator of remodeling. LED-PI would maintain fibroblast activity and viability, and there would be a positive effect on type I collagen (COL1) and basic fibroblast growth factor (bFGF) production from the combination of LED-PI and Cu-GHK incorporation. METHODS: Cell activity/viability, procollagen type I C-peptide (P1CP), and bFGF were evaluated in vitro with human fibroblasts (HS68). The effects of single factors (LED-PI using 0, 1, and 2 J energy doses) or a combination of factors (LED-PI and Cu-GHK) on fibroblast viability (i.e., alamarBlue reduction), collagen production (i.e., P1CP production and COL1 mRNA expression), and bFGF secretion were also evaluated. RESULTS: Reduction in cell viability was significantly suppressed with LED-PI (1 J) and Cu-GHK-supplied incubation. Cell viability was increased 12.5-fold compared with the non-irradiated group (0 J). Collagen production was also increased significantly with LED-PI and Cu-GHK incorporation (197.6 ng/mL). A dose-response effect was observed for LED-PI combined with Cu-GHK. The combinative effects of LED-PI and Cu-GHK led to an increase not only in bFGF secretion (approximately 230%) but also in P1CP production (approximately 30%) and COL1 mRNA expression (approximately 70%) compared with LED-PI alone. CONCLUSION: LED-PI maintained human fibroblast (HS68) viability and increased collagen synthesis when applied by itself. In the combinative stimulation for in vitro collagen production (when LED-PI was followed by Cu-GHK-supplied incubation), stimulated cells showed increased bFGF secretion, P1CP production, and COL1 expression, compared to the LED-PI treatment alone.